Back to User profile » Dr Peng Luo
Papers published by Dr Peng Luo:
Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer
Lin A, Yao J, Cheng Q, Liu Z, Luo P, Zhang J
Journal of Inflammation Research 2023, 16:1693-1709
Published Date: 17 April 2023
B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis
Lin A, Fang J, Cheng Q, Liu Z, Luo P, Zhang J
Journal of Inflammation Research 2022, 15:5541-5555
Published Date: 23 September 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients
Yao Z, Lin A, Yi Y, Shen W, Zhang J, Luo P
Drug Design, Development and Therapy 2022, 16:1679-1695
Published Date: 3 June 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Applications of Machine Learning to Predict Cisplatin Resistance in Lung Cancer
![](cr_data/cache/article_graphical_abstract/s329644/graphical_abstract.jpg)
Gao Y, Lyu Q, Luo P, Li M, Zhou R, Zhang J, Lyu Q
International Journal of General Medicine 2021, 14:5911-5925
Published Date: 21 September 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A novel mutation panel for predicting etoposide resistance in small-cell lung cancer
Qiu Z, Lin A, Li K, Lin W, Wang Q, Wei T, Zhu W, Luo P, Zhang J
Drug Design, Development and Therapy 2019, 13:2021-2041
Published Date: 21 June 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer
Yi L, Zhang W, Zhang H, Shen J, Zou J, Luo P, Zhang J
Drug Design, Development and Therapy 2018, 12:2455-2466
Published Date: 7 August 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap
Zhang X, Chen Y, Fan L, Ye J, Fan J, Xu X, You D, Liu S, Chen X, Luo P
Drug Design, Development and Therapy 2018, 12:2371-2379
Published Date: 1 August 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis
Fan JS, Xia ZF, Zhang XL, Chen YQ, Qian RL, Liu SH, You DM, Zhang J, Luo P
OncoTargets and Therapy 2018, 11:1105-1115
Published Date: 1 March 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Glia maturation factor-β: a potential therapeutic target in neurodegeneration and neuroinflammation
Fan J, Fong T, Chen X, Chen C, Luo P, Xie H
Neuropsychiatric Disease and Treatment 2018, 14:495-504
Published Date: 9 February 2018
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/JVv1FbJs8xc/1.jpg)
Chen Y, Guo W, Fan J, Chen Y, Zhang X, Chen X, Luo P
Cancer Management and Research 2017, 9:801-811
Published Date: 7 December 2017
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer
Guo WJ, Liu SH, Zhang XL, Chen YT, Qian RL, Zou ZY, Chen X, Luo P
Drug Design, Development and Therapy 2017, 11:3367-3376
Published Date: 28 November 2017